EP3980062A4 - Adjuvants for immunogenic compositions and methods of use thereof - Google Patents

Adjuvants for immunogenic compositions and methods of use thereof Download PDF

Info

Publication number
EP3980062A4
EP3980062A4 EP20817707.1A EP20817707A EP3980062A4 EP 3980062 A4 EP3980062 A4 EP 3980062A4 EP 20817707 A EP20817707 A EP 20817707A EP 3980062 A4 EP3980062 A4 EP 3980062A4
Authority
EP
European Patent Office
Prior art keywords
adjuvants
methods
immunogenic compositions
immunogenic
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20817707.1A
Other languages
German (de)
French (fr)
Other versions
EP3980062A1 (en
Inventor
Matthew FRIEMAN
Robert Haupt
Robert K. Ernst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland at Baltimore
Original Assignee
University of Maryland at Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland at Baltimore filed Critical University of Maryland at Baltimore
Publication of EP3980062A1 publication Critical patent/EP3980062A1/en
Publication of EP3980062A4 publication Critical patent/EP3980062A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP20817707.1A 2019-06-06 2020-06-08 Adjuvants for immunogenic compositions and methods of use thereof Pending EP3980062A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962858034P 2019-06-06 2019-06-06
PCT/US2020/036685 WO2020247942A1 (en) 2019-06-06 2020-06-08 Adjuvants for immunogenic compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
EP3980062A1 EP3980062A1 (en) 2022-04-13
EP3980062A4 true EP3980062A4 (en) 2023-07-26

Family

ID=73652646

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20817707.1A Pending EP3980062A4 (en) 2019-06-06 2020-06-08 Adjuvants for immunogenic compositions and methods of use thereof

Country Status (3)

Country Link
US (1) US20220233688A1 (en)
EP (1) EP3980062A4 (en)
WO (1) WO2020247942A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014138696A1 (en) * 2013-03-07 2014-09-12 University Of Maryland, Baltimore Immunotherapeutic potential of modified lipooligosaccharides/lipid a
WO2018067730A1 (en) * 2016-10-04 2018-04-12 University Of Maryland, Baltimore Methods of treating sepsis using anti-sepsis lipid a (asla) based therapeutics

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759241B1 (en) * 1999-10-04 2004-07-06 University Of Maryland Biotechnology Institute Adjuvant comprising a lipopolysaccharide antagonist

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014138696A1 (en) * 2013-03-07 2014-09-12 University Of Maryland, Baltimore Immunotherapeutic potential of modified lipooligosaccharides/lipid a
WO2018067730A1 (en) * 2016-10-04 2018-04-12 University Of Maryland, Baltimore Methods of treating sepsis using anti-sepsis lipid a (asla) based therapeutics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020247942A1 *

Also Published As

Publication number Publication date
EP3980062A1 (en) 2022-04-13
WO2020247942A1 (en) 2020-12-10
US20220233688A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
EP3997115A4 (en) Il-2 compositions and methods of use thereof
EP3843720A4 (en) Compositions of cxcr4 inhibitors and methods of preparation and use
EP3976638A4 (en) Il-2 compositions and methods of use thereof
EP3841090A4 (en) Specially formulated compositions of inhaled nintedanib and nintedanib salts
EP3893917A4 (en) Il-15 compositions and methods of use thereof
EP3576764A4 (en) Kras peptide vaccine compositions and method of use
EP3877381A4 (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
EP3829307A4 (en) Bismuth-thiol compositions and methods of use
EP3606493A4 (en) Dental cement compositions and methods of use
EP3793563A4 (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
EP3934426A4 (en) Preservative compositions and methods of use thereof
EP3830109A4 (en) Methods and compositions for alphavirus vaccine
EP3840769A4 (en) Cyclosporine compositions and methods of use
EP3790552A4 (en) Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
EP4007600A4 (en) Vaccine compositions and methods of selecting antigens
EP4045226A4 (en) Polishing compositions and methods of use thereof
EP4034605A4 (en) Polishing compositions and methods of use thereof
EP3867222A4 (en) Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
EP3999851A4 (en) Compositions and methods for the treatment of tuberculosis
EP3740500A4 (en) Compositions and methods for increasing expression of scn2a
EP3784275A4 (en) Mycobacterial antigen compositions and methods of use
EP3980062A4 (en) Adjuvants for immunogenic compositions and methods of use thereof
EP3923981A4 (en) Vaccine adjuvants and formulations
EP4054514A4 (en) Compositions containing fenchols and methods of use
EP3965776A4 (en) Oligosaccharide compositions and methods of use

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220104

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20230626

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/04 20060101ALI20230620BHEP

Ipc: A61P 31/16 20060101ALI20230620BHEP

Ipc: A61K 39/155 20060101ALI20230620BHEP

Ipc: A61K 39/145 20060101ALI20230620BHEP

Ipc: A61K 39/12 20060101ALI20230620BHEP

Ipc: A61K 39/39 20060101AFI20230620BHEP